股市必读：回盛生物（300871）10月15日董秘有最新回复

Core Viewpoint - The company, Huisheng Biological (300871), is actively expanding its overseas market presence, primarily focusing on the export of raw materials, while its formulation business is still in the exploratory phase [2]. Group 1: Stock Performance - As of October 15, 2025, Huisheng Biological's stock closed at 21.35 yuan, an increase of 1.47%, with a turnover rate of 2.25%, a trading volume of 45,500 shares, and a transaction amount of 96.5641 million yuan [1]. Group 2: Investor Relations - The company has received inquiries regarding its competitiveness in overseas markets and its strategies for international expansion, indicating a positive trend in overseas sales [2]. - The company has not yet provided a third-quarter earnings forecast, with the report scheduled for release on October 28 [2]. - The company is awaiting approval from the China Securities Regulatory Commission for its targeted stock issuance, with the review inquiry response already submitted [2]. Group 3: Market Activity - On October 15, there was a net inflow of 1.2384 million yuan from major funds, suggesting increased short-term interest in Huisheng Biological [2]. - Retail investors showed a net outflow of 1.9195 million yuan, while speculative funds had a net inflow of 0.6811 million yuan [2].